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Cocaine abuse and addiction remain grave health and societal problems with nearly 11,000 
overdose deaths in 2015. Despite the high prevalence of cocaine use, no FDA-approved 
therapeutic for treating cocaine addiction has been achieved. The primary target for cocaine is 
dopamine transporter (DAT) and the rewarding and reinforcing effects of cocaine are 
 Several 
DAT inhibitors have been proposed as potential drugs for cocaine abuse.[1-2] One of the most 
studied DAT inhibitors, GBR12909 (Ki DAT = 3.7 nM), is able to slightly increase DA level 
and to blunt the cocaine-induced elevation of extracellular DA in vivo without exerting the 
central exciting effects of cocaine and addiction. Unfortunately, the phase I clinical trials 
failed, due to its cardiotoxicity.[3-4] In a lead optimisation program focused to identify novel 
and safe GBR12909 analogues, nine constrained derivatives were design and synthesized in a 
ligand based approach. Maintaining unaltered the fluoro-phenyl and phenylpropylpiperazine 
moiety, the rigidification of the ethylene ether, by means of tetrahydrofuran, dioxolane, 
dioxane, oxathiolane and dithiolane ring, was investigated in a focused SAR study (Fig. 1).  
 
 
Fig. 1: Structural modification of the lead compound GBR12909. 
 
All the compounds were assayed for the determination of the binding affinity for DAT, NET 
and SERT. In particular, two dioxolane derivatives displayed a binding affinity comparable to 
that of GBR12909, with Ki of 21.2 and 13.9 nM for DAT, and a selectivity ratio SERT/DAT 
> 30. Since the cyclization introduces one chiral centre, the two enantiomers of one racemic 
mixture were prepared following enantioselective synthetic procedures. The (R)- and (S)-
forms showed a binding affinity comparable to the one determined for the racemate (Ki DAT of 
16 and 46 nM, respectively), suggesting that the configuration of the stereocenters slightly 
affect the binding to the DAT transporter. For the most interesting derivatives, uptake 
inhibition assays were conducted in rat brain synaptosomes. It was observed that the potency 
trend parallel the affinity values. 
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